北陆药业：获得枸橼酸西地那非口崩片《药品注册证书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Sildenafil Citrate Orally Disintegrating Tablets, which is a selective phosphodiesterase type 5 inhibitor used for treating erectile dysfunction [1] Group 1: Product Details - Sildenafil Citrate is known for its rapid onset of action and effective treatment for erectile dysfunction [1] - The orally disintegrating tablet formulation allows for administration without water, dissolving in the mouth within seconds, thus providing a convenient and discreet option for patients [1] - This formulation meets the demand for convenient, fast-acting, and privacy-preserving oral medications among patients [1] Group 2: Market Context - The orally disintegrating tablet is an iteration of the original Sildenafil developed by Pfizer, which was approved for import in China in 2019 [1]